It’s small consolation to someone facing retribution at work for their boss’ indiscretion, but if nothing else your question ...

Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L ...

The rollout of a type of genetic technology called a gene drive for tackling malaria could be edging closer after a lab study ...

This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...

Journalist Amy Robach reflects on her journey—and how women like Rebecca are reclaiming their lives after diagnosis.

Slowly tapering antidepressants with psychological support prevents depression relapse to a similar extent as continuing the medication, a new analysis shows.

The SERENA-6 trial shows a 54% reduced risk of death with camizestrant, with a median PFS of 16.6 months versus 9.2 months ...

Among patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis (MPGN), ...

TARGETED treatments for prostate cancer were a central theme at the European Society for Medical Oncology (ESMO) Congress ...

When cells can’t destroy damaged proteins, a hidden backup system led by NRF1 steps in to prevent toxic buildup.